Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
A Phase 2 trial is underway to evaluate the efficacy of nivolumab and ipilimumab in treating EBV-driven nasopharyngeal carcinoma.
Therapeutic Area
Therapeutic area intelligence for Immuno-Oncology with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.